## ACLX: Arcellx, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($60.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Arcellx (NASDAQ: ACLX) iMMagine-1 shows 96% ORR, 74% CR/sCR in Phase 2 RRMM**
- Source: Stock Titan | 20251207T052055 | Bullish | Relevance: 98%
-  Arcellx Inc. announced positive new data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma (RRMM). The study demonstrated a 96% overall response rate and a 74% complete response/stringent complete response rate, with responses deepening over time and high rates of minimal residual disease negativity. The company maintains its plan for a 2026 commercial launch, pending FDA approval, highlighting anito-cel's potential as a significant new CAR T treatment option.

**2. New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment**
- Source: STAT | 20251207T162055 | Bullish | Relevance: 98%
- Gilead Sciences and Arcellx reported strong, durable responses and no new safety concerns for their CAR-T therapy, anito-cel, for multiple myeloma. Data presented at the American Society of Hematology meeting showed that 96% of 117 patients in a pivotal trial responded, with 74% achieving complete remission. Gilead aims to secure approval and begin selling the treatment next year.

**3. Arcellx announces new data for its iMMagine-1 study in patients with RRMM**
- Source: TipRanks | 20251207T172055 | Bullish | Relevance: 98%
-  Arcellx (ACLX) announced positive new data from its pivotal Phase 2 iMMagine-1 study for anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma (RRMM). The data, presented at the 67th American Society of Hematology Annual Meeting, showed a 96% overall response rate and high rates of complete response and MRD negativity. The therapy demonstrated strong progression-free and overall survival rates over 24 months, with median PFS and OS not yet reached.

**4. Trading the Move, Not the Narrative: (ACLX) Edition**
- Source: Stock Traders Daily | 20251207T161600 | Somewhat-Bullish | Relevance: 98%
-  An analysis of Arcellx Inc. (NASDAQ: ACLX) reveals a mid-channel oscillation pattern, with weak near and mid-term sentiment contrasting a strong long-term positive outlook. The article presents an exceptional risk-reward setup targeting a 17.6% gain against 0.3% risk and outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and holding periods for ACLX.

**5. Arcellx Inc. Stock Surge: Time to Buy?**
- Source: StocksToTrade | 20251208T191005 | Bullish | Relevance: 98%
- Arcellx Inc. (NASDAQ: ACLX) stock surged 9.32% following positive Phase 2 iMMagine-1 study results for its multiple myeloma therapy and plans for a 2026 commercial launch. Analysts maintain a bullish outlook despite competitive concerns, with Wolfe Research initiating coverage. The company's financial snapshot shows strong gross margin potential and sturdy cash holdings despite negative EBIT, suggesting investor confidence in future growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Canaccord Genui | $130 | $130 | 0% |
| 2025-12-08 | Needham | $105 | $105 | 0% |
| 2025-11-18 | Wolfe Research | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Canaccord Genui | main | Buy |
| 2025-12-08 | Needham | reit | Buy |
| 2025-11-18 | Wolfe Research | init | Peer Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 9 ($2.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 1 / 5 |

**Top Holders:**
- Gilead Sciences Inc: 11.6% (0.0%)
- T. Rowe Price Invest: 11.0% (+226.8%)
- FMR, LLC: 10.0% (-3.5%)
- Paradigm Biocapital : 8.0% (0.0%)
- Vanguard Group Inc: 6.8% (-1.0%)

### Key Risks

1. Elevated short interest (13.9%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.49). Revenue growth strong at 288% YoY. Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (1 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.1B |
| Beta | 0.34 |
| 52W Range | $47.86 - $94.07 |
| Short Interest | 13.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -8.2% to -1.6% (+6.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. MACD histogram bearish (-0.91), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.55% (CS: 42) | Neutral |
| RSI_14 | 37.9 | Neutral |
| MACD Histogram | -0.91 | Bearish |
| vs SMA20 | 0.888x | Below |
| vs SMA50 | 0.846x | Below |
| vs SMA200 | 0.992x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $70.84
- **Stop Loss:** $60.44 (14.7% risk)
- **Target:** $81.24 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 28
- **Position Value:** $1,983.52
- **Portfolio %:** 1.98%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-26 (Est: $-1.06)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.03 | $-0.99 | +4.1% |
| 2025Q2 | $-1.03 | $-0.94 | +8.9% |
| 2025Q1 | $-0.74 | $-1.13 | -53.0% |
| 2024Q4 | $-0.47 | $-0.87 | -83.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*